Clairvoyant Therapeutics, a clinical stage biotech company focused on the development of psychedelic drug therapies for the treatment of addiction, is pleased to announce the first patient has been dosed in the company’s Phase 2 clinical trial investigating psilocybin for the treatment of alcohol use disorder (AUD). Clairvoyant’s randomized, controlled, clinical trial, CLA-PSY-201, will evaluate…